Improved overall survival in melanoma with combined dabrafenib and trametinib.

Robert, Caroline

Improved overall survival in melanoma with combined dabrafenib and trametinib. [electronic resource] - The New England journal of medicine Jan 2015 - 30-9 p. digital

Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1533-4406

10.1056/NEJMoa1412690 doi


Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Female
Humans
Imidazoles--administration & dosage
Indoles--adverse effects
Intention to Treat Analysis
Kaplan-Meier Estimate
Male
Melanoma--drug therapy
Middle Aged
Mitogen-Activated Protein Kinase Kinases--antagonists & inhibitors
Mutation
Oximes--administration & dosage
Protein Kinase Inhibitors--administration & dosage
Proto-Oncogene Proteins B-raf--antagonists & inhibitors
Pyridones--administration & dosage
Pyrimidinones--administration & dosage
Skin Neoplasms--drug therapy
Sulfonamides--adverse effects
Survival Analysis
Vemurafenib
Young Adult